SCHEMBL30181963

SCHEMBL30181963

CC(C)(C)OC(=O)N1C[C@@H](N2CCCC2)[C@@H](F)C1

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 1/20 0.49
▸ NR1H2 P55055 1/20 0.43
▸ USP30 Q70CQ3 2/20 0.42
▸ PREP P48147 2/20 0.42
▸ USP2 O75604 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ RECQL P46063 1/20 0.40
▸ EPHX1 P07099 1/20 0.40
▸ MEN1 O00255 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ PIK3R1 P27986 2/20 0.39
▸ PIK3CA P42336 2/20 0.39
▸ HSD17B10 Q99714 1/20 0.37
▸ RORC P51449 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL391389 1.00 HPGD (0.49) HPGDNR1H2USP30PREPUSP2
SCHEMBL24032920 1.00 HPGD (0.49) HPGDNR1H2USP30PREPUSP2
SCHEMBL1993166 0.88 HPGD (0.54) HPGDPREPUSP2SMN1; SMN2RECQL
SCHEMBL1993163 0.88 HPGD (0.54) HPGDPREPUSP2SMN1; SMN2RECQL
SCHEMBL24183594 0.87 HPGD (0.56) HPGDPREPUSP2SMN1; SMN2RECQL
SCHEMBL12926558 0.85 HPGD (0.50) HPGDPREPUSP2SMN1; SMN2RECQL
SCHEMBL31691884 0.84 HPGD (0.48) HPGDNR1H2USP30PREPUSP2
SCHEMBL390405 0.83 HPGD (0.47) HPGDNR1H2PREPUSP2SMN1; SMN2
SCHEMBL4343676 0.83 HPGD (0.47) HPGDNR1H2PREPUSP2SMN1; SMN2
SCHEMBL30181772 0.83 HPGD (0.47) HPGDNR1H2PREPUSP2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11806346-B2 HTT modulators for treating Huntington's disease CHDI FOUNDATION, INC. (US) 2023-11-07 — — US disclosed
EP-4149937-A1 HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE CHDI Foundation, Inc. (US) 2023-03-22 — — EP disclosed
US-20220409615-A1 HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE CHDI FOUNDATION, INC. 2022-12-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220409615-A1 HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE HTT, HYPK, ATXN2 HPGD 2137/4885NR1H2 1722/4885USP30 1202/4885
US-11806346-B2 HTT modulators for treating Huntington's disease HTT, HYPK, ATXN2 HPGD 2137/4885NR1H2 1722/4885USP30 1202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback